AC	anticoagulation
ACE	angiotensin-converting enzyme
ACE2	angiotensin-converting enzyme-2
ACEIs	angiotensin-converting enzyme inhibitors
ACTIV-4	anti-thrombotic for adults hospitalized with COVID-19
ADAM17	a disintegrin and metalloproteinase domain-containing protein 17
AF	atrial fibrillation
AI	anemia of inflammation
ARDS	acute respiratory distress syndrome
AT	antithrombin
ATTACC	antithrombotic therapy to ameliorate complications of COVID-19
AT1	angiotensin I
AT1-5	angiotensin 1-5
AT1-7	angiotensin 1-7
AT1-9	angiotensin 1-9
AT2	angiotensin II
AT1R	angiotensin I receptor
BBM	duodenal brush border membranes
CAD	coronary artery disease
CaM	calmodulin
CI	confidence interval
CRP	c-reactive protein
DM	diabetes
DIC	disseminated intravascular coagulation
DOACs	direct oral anticoagulants
DVT	deep vein thrombosis
ED	emergency department
EDTA	ethylenediaminetetraacetic acid
Fc	fragment crystallizable region
GPVI	platelet membrane glycoprotein
HF	heart failure
HR	hazard ratio
hrsACE2	human recombinant soluble ACE2
ICU	intensive care unit
IFN-α	interferon-alpha
IL	interleukin
LA	left atrial
LDL	low-density lipoprotein
LMWH	low molecular weight heparin
LVEF	left ventricular ejection fraction
MACE	major adverse cardiovascular events
NOS	nitric oxide synthase
NRP1	neuropilin-1
NYHA	New York Heart Association
OR	odds ratio
PE	pulmonary embolism
PT	prothrombin time
PURE	Prospective Urban Rural Epidemiology
RBD	receptor binding domain
REMAP-CAP	randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia
SARS-CoV-1	severe acute respiratory syndrome coronavirus
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SARSr-CoVs	severe acute respiratory syndrome-related coronaviruses
SEMA3A	semaphorin 3A
TMPRSS2	transmembrane serine protease 2
TNF-α	tumor necrosis factor-alpha
UFH	unfractionated heparin
VTE	venous thromboembolism